[go: up one dir, main page]

AU2886292A - Compositions and methods for treatment of epstein-barr virus-associated diseases - Google Patents

Compositions and methods for treatment of epstein-barr virus-associated diseases

Info

Publication number
AU2886292A
AU2886292A AU28862/92A AU2886292A AU2886292A AU 2886292 A AU2886292 A AU 2886292A AU 28862/92 A AU28862/92 A AU 28862/92A AU 2886292 A AU2886292 A AU 2886292A AU 2886292 A AU2886292 A AU 2886292A
Authority
AU
Australia
Prior art keywords
epstein
compositions
treatment
methods
barr virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28862/92A
Inventor
Kevin P Anderson
David J Ecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2886292A publication Critical patent/AU2886292A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU28862/92A 1991-10-25 1992-10-23 Compositions and methods for treatment of epstein-barr virus-associated diseases Abandoned AU2886292A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78360591A 1991-10-25 1991-10-25
US783605 1991-10-25

Publications (1)

Publication Number Publication Date
AU2886292A true AU2886292A (en) 1993-05-21

Family

ID=25129820

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28862/92A Abandoned AU2886292A (en) 1991-10-25 1992-10-23 Compositions and methods for treatment of epstein-barr virus-associated diseases

Country Status (3)

Country Link
AU (1) AU2886292A (en)
NZ (1) NZ244820A (en)
WO (1) WO1993007882A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649734B2 (en) * 1990-08-16 1994-06-02 Isis Pharmaceuticals, Inc. Inhibition of candida
AU656136B2 (en) * 1990-04-20 1995-01-27 General Hospital Corporation, The Methods of preventing viral replication
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
AU1878895A (en) * 1994-02-18 1995-09-04 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US5550047A (en) * 1994-02-18 1996-08-27 University Of Massachusetts Oligonucleotides with anti-Epstein-Barr virus activity
GB9413035D0 (en) * 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5837854A (en) * 1996-04-05 1998-11-17 University Of Massachusetts Oligonucleotides with anti-Epstein-Barr virus activity
CA2321654C (en) 1998-03-04 2011-02-15 Marcel Bartolina Hendrikus Johannes Vervoort Oligonucleotides for the amplification and detection of epstein barr virus (ebv) nucleic acid
CA2370108A1 (en) * 1999-04-30 2000-11-09 Advance Sentry Corporation System and method for screening of nasopharyngeal carcinoma
US20070299027A1 (en) * 2006-01-26 2007-12-27 Gene Hung Compositions and their uses directed to huntingtin
EP3342415B1 (en) 2006-08-08 2022-01-26 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
JP5689413B2 (en) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 5 'triphosphate oligonucleotide having blunt ends and uses thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656136B2 (en) * 1990-04-20 1995-01-27 General Hospital Corporation, The Methods of preventing viral replication
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
AU649734B2 (en) * 1990-08-16 1994-06-02 Isis Pharmaceuticals, Inc. Inhibition of candida

Also Published As

Publication number Publication date
WO1993007882A1 (en) 1993-04-29
NZ244820A (en) 1994-01-26

Similar Documents

Publication Publication Date Title
AU4214193A (en) Bioadhesive treatment compositions and method of use
AU6446490A (en) Disinfectant composition and method of disinfection
AU3368595A (en) Methods of inhibiting demyelinating and dysmyelinating diseases
AU2886292A (en) Compositions and methods for treatment of epstein-barr virus-associated diseases
AU8910891A (en) Treatment of lung diseases
AU7650396A (en) Treatment and prophylaxis of osteoporosis
AU5960394A (en) Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
AU5605398A (en) Novel methods and compositions for treatment of autoimmune diseases
AU2180097A (en) Composition for prevention and treatment of periodontal diseases
AU8192691A (en) Method of treatment and compositions therefore
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
IL107768A0 (en) Treatment of agricultural produce
AU7609094A (en) Treatment and prophylaxis of diseases caused by parasites or bacteria
AU3263795A (en) Medicament for treatment or prophylaxis of incontinence
AUPN380695A0 (en) Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
AU3027692A (en) Compositions for the treatment of mammalian diseases
AU3607597A (en) Pharmaceutical composition for prophylaxis and/or treatment of apoptosis-related diseases
AU4104093A (en) Method and compositions for treatment of pyonecrotic processes
AU7120987A (en) Composition for and method of treating aids and certain related diseases
AU5293293A (en) Methods and compositions for treatment of allergic disease
AU5425098A (en) Compounds and methods to treat infectious diseases
AU4819993A (en) Drug for treatment and prophylaxis of bone and joint diseases
AU4604697A (en) Compositions and methods for the treatment of human cytomegalovirus infection
AU2754997A (en) The treatment of plant diseases
AU4319393A (en) Use of indolocarbazols in aids treatment